Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More
Latest News

Committed to Supporting Clients During the COVID-19 Pandemic

Access resources and information related to COVID-19 studies to discover how we are joining the COVID-19 fight

Learn More
White Paper

Integrated Scientific Advice during the COVID-19 Pandemic: A Status Update on Key Programs in North America and Europe

Gain insight into the latest updates on sponsors seeking integrated scientific advice during the COVID-19 pandemic

Read Now
White Paper

US FDA’s Coronavirus Treatment Acceleration Program (CTAP)

Read our special feature to gain insight into CTAP as well as a recommended strategy for pharmaceutical companies with COVID-19 programs

Read Now
Upcoming Webinar

Incorporating Innovation into the 505(b)2 Development Pathway

Thursday, August 13, 2020 | 10:00AM EDT

Register Now
The Evidence Forum

The spring issue of The Evidence Forum is out

Read content related to the relevant issues facing companies along the path to approval and access, including a focus section on digital technologies

Read Now

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Immunology

Oral Corticosteroid Treatment Patterns of Patients in the United States With Persistent Asthma

  • Journal of Allergy and Clinical Immunology
  • August 2020
Rheumatology

What Do Australian Patients with Inflammatory Arthritis Value in Treatment? A Discrete Choice Experiment

  • Clinical Rheumatology
  • July 2020
Infectious Disease

Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV

  • Patient
  • July 2020
Read More About Our Publications
What We Do

What We Do

Real-World Evidence

Obtain real-world evidence of value by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Market Access

Optimize market access with cogent payer insights, expert-informed evidence strategy, and persuasive communication of product value.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Pragmatic Studies

Explore patient-centered outcomes and comparative effectiveness using pragmatic studies with adaptive designs.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.

In Our Own Words

There is an increasing desire from regulators and HTA bodies to provide patient-centric integrated scientific advice (ISA) earlier in the technologies development process. Our ISA offering supports clients by generating evidence that meets all stakeholder needs, ensuring timely patient access and commercial success.

Case Study

Enhancing Oncology Market Access with a Real-World Evidence EAMS Add-on

Discover how Evidera researchers designed an observational study to conceptualize and implement real-world data collection in an Early Access to Medicines Scheme (EAMS) for an oncology therapy.

Read More
Case Study

Evidera Led Effort to Qualify the First Biomarker for COPD Trial Enrichment

Learn how Evidera's partnership with the COPD Foundation Biomarker Qualification Consortium led to the qualification of plasma fibrinogen as the first biomarker in COPD for enrichment of clinical trials by the FDA.

Read More
Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More